Key facts
- This page summarizes Melissa B. Epperly's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Oct 2022, 18:42.
Melissa B. Epperly - 03 Oct 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ZNTL
- Reported as of
- 03 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Oct 2022, 18:42:44 UTC
- Prior SEC filing
- 25 Jul 2022
- Next SEC filing
- 01 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Melissa B. Epperly
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Melissa B. Epperly filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 03 Oct 2022.
Change
- Previous filing in this sequence was filed on 25 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZNTL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +20%
- Price
- $0.000000
- Shares after
- 297,543
- Date
- 03 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted by the Issuer under the 2020 Incentive Award Plan, as amended. The RSUs will vest over two years: 1/3 of the RSUs will vest on the first anniversary of the date of grant, and the remaining 2/3 of the RSUs will vest on the second anniversary of the date of grant.
Footnote F2
Includes 129 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2022.